Clinical-stage biopharmaceutical company vTv Therapeutics Inc. is at the forefront of developing orally administered treatments for diabetes. The company's standout drug candidate, liver-selective glucokinase activator TTP399, aims to bring relief to type 1 diabetes sufferers. vTv Therapeutics Inc. is also developing non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor HPP737, which targets inflammatory diseases and psoriasis. A host of other programs are also in the works, including medication for cystic fibrosis related diabetes and a therapeutic approach to activating the Nrf2 pathway for chronic diseases associated with oxidative stress. Additionally, the RAGE antagonist azeliragon could prove a valuable tool in fighting lung inflammation diseases, breast and pancreatic cancers and severe COVID-19. The company holds a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including HPP593. vTv Therapeutics Inc. additionally holds license and research agreements with industry players Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International and Novo Nordisk A/S. Since its 2015 incorporation, vTv Therapeutics Inc. has been headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.
vTv Therapeutics Inc.'s ticker is VTVT
The company's shares trade on the NASDAQ stock exchange
They are based in High Point, North Carolina
There are 11-50 employees working at vTv Therapeutics Inc.
It is https://vtvtherapeutics.com/
vTv Therapeutics Inc. is in the Healthcare sector
vTv Therapeutics Inc. is in the Biotechnology industry
The following five companies are vTv Therapeutics Inc.'s industry peers: